Business
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
About this update from Clearpoint Neuro Inc.
[{"type":"text","content":"Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (\"Company\"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototype system. This device was built in partnership with the SONOCARELAB, at Sungkyunkwan University in Suwon, South Korea on the Natural Science Campus.\"This milestone has been nearly four years in the making, and demonstrates our continuous pursuit to be the most complete neuro navigation and therapy enabling company in the world\", commented Joe Burnett, President and CEO of the Company. \"Focused Ultrasound has tremendous potential, and has been studied across many applications including drug delivery, tissue ablation, liquid biopsy and even standalone treatments for neurological disorders like Alzheimer's Disease. By leveraging our 15 years of neuro navigation software development, and by deploying focused ultrasound using our planned robotic platform in a traditional OR setting, we believe the ClearPoint and SONOCARELAB solution will fit perfectly into our four-pillar growth strategy.\" Note: Image showing successful delivery of large molecule FITC Dextran Tracer and Evans Blue Tracers across the blood-brain barrier and consistent with the planned focal acoustic beam trajectory in large subject preclinical testing.\"Our goal is to offer the most complete portfolio possible to our biopharma partners to enable successful, targeted drug delivery to the brain\", commented Jeremy Stigall, Chief Business Officer & General Manager of Biologics and Drug Delivery at ClearPoint Neuro, Inc. \"Focused ultrasound will be a tool, and not the tool, in our drug delivery ecosystem, and will be deployed alongside our other routes-of-administration based on drug type, target, and indication. Some biopharma partners will continue to use our SmartFlow cannul...